Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026
Key Highlights
- ➤Q3 revenue $9.9 million, down approximately 22.0% year over year
- ➤Q3 operating loss $1.0 million versus $0.2 million operating income
- ➤Q3 net loss $0.7 million versus $0.1 million net income
- ➤Two largest contract manufacturing customers represented 88% of Q3 revenue
Expert Statements
Riva Sheppard, Co-Chief Executive Officer of Integrated BioPharma
“Our revenue decreased by approximately 22% in the quarter ended September 30, 2026 from the quarter ended September 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 88% and 87% of total revenue in the quarters ended September 30, 2026 and 2025, respectively.”
Christina Kay, Co-Chief Executive Officer of Integrated BioPharma
“Our revenue decreased by approximately 22% in the quarter ended September 30, 2026 from the quarter ended September 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 88% and 87% of total revenue in the quarters ended September 30, 2026 and 2025, respectively.”
HILLSIDE, NJ / ACCESS Newswire / November 13, 2026 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2026. Revenue for the quarters ended September 30, 2026 was $9.9 million compared to $12.7 million for the quarter ended September 30, 2025, a decrease of $2.8 million or approximately 22.0%. The Company had an operating loss of $1.0 million in the quarter ended September 30, 2026 compared to operating income of $0.2 million for the quarter ended September 30, 2025.
For the quarter ended September 30, 2026, the Company had a net loss of approximately $0.7 million compared to net income of approximately $0.1 million for the quarter ended September 30, 2025 or $(0.02) and $0.00 per share of common stock, respectively. The Company's diluted net (loss) income per share of common stock for the quarters ended September 30, 2026 and 2025 were $(0.02) and $0.00 per share of common stock, respectively.
Get started
Create a free account to read the full story.